Skip to content

Author

Jay B. Maheta

We have 3 of 12 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Click chemistry-assisted synthesis of benzimidazole-1,2,3-triazole hybrids as potential anticancer and antioxidant agents: Integrated in vitro, in silico docking, ADMET, molecular dynamics, and DFT studies

Abstract This study details the rational design and synthesis of benzimidazole–1,2,3-triazole hybrids (10a-10o) as potential CDK2 inhibitors for anticancer treatment. Molecular docking showed strong binding within the ATP-binding site, with key hydrogen bonds to Leu83 and Asp86, as well as hydrophobic and π–π interacti...

Dharmesh A. Patel, R. Dabhi, Apurva Prajapati et al. · 0 citations
Aug 2026

Design, synthesis and dual anticancer and antibacterial evaluation of novel 1,3,4-oxadiazole-2-thiol derivatives targeting EGFR and DNA Gyrase B: integrated docking, DFT and ADMET studies.

1,3,4-oxadiazole-2-thiol derivatives are established as promising dual-action therapeutic scaffolds for anticancer and antibacterial activities through computational and experimental approaches.

Ila M. Ram, Jay B. Maheta, Darshna K. Lakhnotra et al. · 0 citations
Aug 2026

Potential c-Met-targeted pyrazole-pyridine-oxadiazole hybrids: synthesis, anticancer activity, and computational rationale.

Findings identify 10d as a promising scaffold for further optimization and biological evaluation because it has the smallest HOMO-LUMO gap and highest chemical softness, consistent with its superior activity.

Prince A. Dave, Jay B. Maheta, Darshna K. Lakhnotra et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.